Loading
Distinct shells carrying a filed role for this person — not every shell they have ever touched.
SEC-verified vehicles of the same sponsor, predating these roles and carrying none of them. The badge counts them; the figure beside this one does not.
Mergers closed across all 2 — these vehicles and the franchise's earlier ones together.
Announced but not closed, and still hunting — again over all 2.
No closed vehicle here has both a stored price and a filed trust value to score it against.
1 vehicle on file, newest listing first
none appears on more than one
Daniel Hume , 58, has served on our board of directors since October 28, 2025. Mr. Hume currently serves as the Managing Partner of Kirby McInerney, LLP, where his practice focuses on securities law regulation, structured finance, antitrust, and civil litigation, and where he has practiced law since 1995. Since June 2015, Mr. Hume has served as a director of TG Therapeutics, Inc., a public biopharmaceutical company and Lirum Therapeutics, a private biopharmaceutical company. Previously, Mr. Hume was a director of Stemline Therapeutics Inc., a late clinical stage 146 Table of Contents biopharmaceutical company, from 2017 to 2021, and National Holdings Corporation, a financial services company, from 2016 to 2021, until those companies’ successful acquisitions. Mr. Hume earned a B.A. in philosophy from the State University of New York at Albany and earned a J.D. from the Columbia University Law School. We believe Mr. Hume is qualified to serve on our board of directors because of his extensive legal experience and experience serving as a public company director.
This record is keyed to SEC CIK 0001645514 — the identifier this person files under in their own name. Every vehicle above is a filing made under that CIK, so “the same person on two shells” is a fact about an SEC identifier rather than about a name that happens to match.
Roles are the strings the filings used, in the order they were filed. Nothing on this page ranks them, infers seniority, or offers a reason why any two of these names recur — a recurrence is a count, and the filings that produced it are linked beside every row. We also hold 5 institutional-holder rows on these vehicles, under 4 distinct name strings, and none of them is counted across vehicles: that table has no CIK column, and matching holders by name would merge firms that are not the same firm.